Sobi, Inc.
Clinical trials sponsored by Sobi, Inc., explained in plain language.
-
New hope for kids with bleeding disorder: drug boosts platelets in phase 3 trial
Disease control CompletedThis study tested a medication called avatrombopag in 75 children aged 1 to 17 with immune thrombocytopenia (ITP) lasting at least 6 months. ITP is a condition where the immune system destroys platelets, raising the risk of bruising and bleeding. The goal was to see if the drug c…
Phase: PHASE3 • Sponsor: Sobi, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for low platelets: avatrombopag tested in japanese ITP patients
Disease control CompletedThis study tested a drug called avatrombopag in 19 Japanese adults with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, raising bleeding risk. The goal was to see if the drug could safely increase platelet counts over 26 weeks. Parti…
Phase: PHASE3 • Sponsor: Sobi, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC